Cumulus Neuroscience Presents Data on Digital Cognitive Task for Alzheimer's Trials
Cumulus Neuroscience presented findings from its two-minute digital Symbol Swap task, demonstrating its ability to differentiate cognitive function levels relevant to Alzheimer's research.
Digital health company Cumulus Neuroscience shared data from its Symbol Swap task, a two-minute tablet-based cognitive assessment, indicating its effectiveness in screening for Alzheimer's disease.
Results from three independent studies showed that Symbol Swap matched or surpassed established clinical cognitive screening tests such as ADAS-Cog, MoCA, and MMSE in identifying differences between control individuals, those with mild cognitive impairment (MCI), and individuals with Alzheimer's dementia. The task also correlated with Alzheimer's pathology identified by blood biomarkers, even in individuals who appeared cognitively normal on standard tests.
The company suggests that the digital nature of Symbol Swap reduces the burden on participants and research centers due to its quick administration and automatic scoring. Cumulus Neuroscience believes this tool can enhance the pre-screening process for Alzheimer's clinical trials, potentially lowering screen failure rates and accelerating participant recruitment.
"It is remarkable that a two-minute, patient-friendly task can match or even exceed assessments that require 10 to 45 minutes of trained professional administration, and detect Alzheimer's pathology even in participants who appear cognitively normal," stated Dr. Brian Murphy, co-founder and chief scientific officer at Cumulus Neuroscience. "These data support Symbol Swap as a powerful pre-screening tool."